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Abstract
Background: Tumor cell invasion into adjacent normal brain is a mesenchymal feature of GBM and a major factor
contributing to their dismal outcomes. Therefore, better understandings of mechanisms that promote
mesenchymal change in GBM are of great clinical importance to address invasion. We previously showed that the
bHLH transcription factor TWIST1 which orchestrates carcinoma metastasis through an epithelial mesenchymal
transition (EMT) is upregulated in GBM and promotes invasion of the SF767 GBM cell line in vitro.
Results: To further define TWIST1 functions in GBM we tested the impact of TWIST1 over-expression on invasion
in vivo and its impact on gene expression. We found that TWIST1 significantly increased SNB19 and T98G cell line
invasion in orthotopic xenotransplants and increased expression of genes in functional categories associated with
adhesion, extracellular matrix proteins, cell motility and locomotion, cell migration and actin cytoskeleton
organization. Consistent with this TWIST1 reduced cell aggregation, promoted actin cytoskeletal re-organization
and enhanced migration and adhesion to fibronectin substrates. Individual genes upregulated by TWIST1 known to
promote EMT and/or GBM invasion included SNAI2, MMP2, HGF, FAP and FN1. Distinct from carcinoma EMT,
TWIST1 did not generate an E- to N-cadherin “switch” in GBM cell lines. The clinical relevance of putative TWIST
target genes SNAI2 and fibroblast activation protein alpha (FAP) identified in vitro was confirmed by their highly
correlated expression with TWIST1 in 39 human tumors. The potential therapeutic importance of inhibiting TWIST1
was also shown through a decrease in cell invasion in vitro and growth of GBM stem cells.
Conclusions: Together these studies demonstrated that TWIST1 enhances GBM invasion in concert with
mesenchymal change not involving the canonical cadherin switch of carcinoma EMT. Given the recent recognition
that mesenchymal change in GBMs is associated with increased malignancy, these findings support the potential
therapeutic importance of strategies to subvert TWIST1-mediated mesenchymal change.
Background
Invasion is arguably the feature of human glioblastoma
(GBM) most responsible for their dismal outcomes with
average survival less than 1 year. Diffuse tumor invasion
into adjacent brain restricts curative resection and limits
effective delivery of chemotherapy and radiation. In
addition, migratory GBM cells can activate mechanisms
that increase resistance to these therapies further com-
pounding efforts to eradicate them. Despite the impor-
tance of glioma invasion, little is known about how this
complex phenotype is regulated in gliomas, a prerequi-
site to development of effective anti-invasion therapies.
By contrast, the process by which human epithelial can-
cers, or carcinomas, acquire an invasive phenotype has
been more extensively characterized at both the cellular
and molecular levels.
Carcinoma invasion and metastasis are driven by a
process termed epithelial to mesenchymal transition
(EMT) (For review see [1]). Mesenchymal transitions
lead to acquired potential for cell migration, changes in
cytoskeletal organization, reduced cellular adhesion and
changes in expression of transcription factors. Among
the transcription factors that play fundamental roles in
regulating these changes is the basic helix-loop-helix
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of embryonic morphogenesis [2], tissue fibrosis [3,4]
and cancer metastasis [5-7]. A central feature of
TWIST1-mediated EMT is the repression of the epithe-
lial marker E-cadherin, and activation of the mesenchy-
mal marker N-cadherin [5-7], a hallmark feature of
carcinoma EMT termed the “cadherin switch”.T h e
recent recognition of mesenchymal change in glioblas-
toma [8-10] and its association with more aggressive
clinical phenotypes [8,9] suggests that mechanisms that
promote EMT in carcinoma may be of great clinical
relevance in GBM.
We previously reported that TWIST1 is up-regulated
in malignant gliomas and promotes glioma cell inva-
sion of the SF767 glioma cell line in vitro [11]. How-
ever, the role of TWIST1 in promoting glioma
invasion has not been investigated in the context of
the brain microenvironment or as a mediator of
mesenchymal change as occurs in carcinomas. In addi-
tion, the identification and clinical relevance of puta-
tive TWIST1 target genes in GBMs is not known. In
this study we report that TWIST1 promoted GBM
invasion through activation of mesenchymal molecular
and cellular changes. This effect was not dependent on
a “cadherin switch” indicating that TWIST1 promotes
invasion through mesenchymal changes distinct from
those associated with carcinoma EMT. The highly cor-
related expression of TWIST1 and mesenchymal target
genes SNAI2 and FAP in human gliomas supported
the clinical relevance of TWIST1 mesenchymal change.
Together these results demonstrated an important role
of TWIST1 in glioma invasion through activation of
mesenchymal change and suggest its potential as a
therapeutic target.
Results
TWIST1 regulates invasion of multiple GBM cell lines in
vitro
To extend our previous observation that TWIST1
enhanced invasion of the SF767 GBM cell line in vitro
[11], we studied the effects of TWIST1 over-expression
on invasion of SNB19 and T98G GBM cells using matri-
gel transwell assays. Compared with controls, over-
expression of TWIST1 in SNB19 cells (SNB19 TW) and
T98G cells (T98G TW) resulted in an increase of inva-
sion of 68% and 80%, respectively (Additional file 1).
The pro-invasive function of TWIST1 was also con-
firmed in a well-characterized primary GBM stem cell
line (GBM4) [12] where a five-fold increase in TWIST1
expression resulted in a 140% increase in invasion in
vitro (Additional file 2). Together, these results solidly
established the physiologic importance of TWIST1 for
GBM invasion by demonstrating its uniformly pro-inva-
sive function in multiple GBM cell lines in vitro.
TWIST1 promotes GBM cell invasion in brain slice cultures
and intact brain in vivo
To demonstrate pro-invasive TWIST1 function in more
clinically relevant contexts, we characterized the growth
patterns of SNB19 TW, T98G TW and corresponding
control cells in an ex vivo model using organotypic
brain slice cultures and in vivo using an orthotopic
xenotransplant model. In ex vivo analyses, both SNB19
TW and T98G TW cells were significantly more inva-
sive than control cells (Figure 1). Confocal microscopy
confirmed that cells invaded into the brain slice rather
than simply migrating along the surface. For SNB19,
TWIST1 over-expression resulted in significantly
increased distances of invasion compared with control
cells when measured as orthogonal distances of cell
migration from the border of the cohesive cell aggregate
(p = 0.0002) (Figure 1A). T98G control cells placed on
the brain slice formed a cohesive cell aggregate but
T98G TW cells did not form a central cohesive core in
7 of 8 slices and diffused from the implant site into the
brain slice as small cell clumps (Figure 1B). Therefore,
for T98G we analyzed invasive cell density through the
entire thickness of the brain slice using orthogonal
reconstruction of confocal optical slices. Results shown
in Figure 1B demonstrate that invading density of T98G
TW cells is 4 fold higher compared to invading cell den-
sity of control cells.
To determine whether TWIST1 over-expression
increased invasion in the intact brain, we implanted
SNB19 TW and T98G TW and corresponding control
cells stably expressing GFP protein into the caudate
nucleus of immuno-compromised adult mice (SNB19
TW (n = 6), control (n = 4); T98G TW and control (n
= 3 each)). All animals were sacrificed when neurologic
morbidity was apparent in the first animal (day 17 for
SNB19 and day 90 for T98G). Whole brain fluorescent
imaging by laser scanning confocal microscopy followed
by computer-aided digital image reconstruction provided
a comprehensive global comparison of the tumor
growth patterns throughout the entire brain of each ani-
mal. SNB19 TW and control tumors all met criteria for
Type 2 pattern of invasion with a central core sur-
rounded by individual invasive cells and cell aggregates.
Therefore, to determine differences in invasiveness
between SNB19 TW and control tumors we used Huy-
g e n si m a g ea n a l y s i ss o f t w a r et oq u a n t i f yt h en u m b e ro f
fluorescent particles detected as discrete objects separate
from the tumor core (indicating migratory tumor cells
or clumps), the composite volume of these particles for
each tumor and finally the core tumor volumes. A
representative reconstructed tumor slice volume show-
ing cores and invasive particles is shown in Figure 2A.
This analysis demonstrated a significant increase in the
number of discrete aggregates separate from the tumor
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Page 2 of 18cores and the volume of the invasive particles in tumors
with TWIST1 over-expression compared to control
tumors (p = 0.0037 and p = 0.0166, respectively) (Figure
2B, C) and a trend towards larger mean tumor core
volume in SNB19 TW tumors (p = 0.11). All T98G con-
trol tumors grew as localized expansile masses (Type 1
growth pattern) while all T98G TW tumors generated
markedly invasive tumors that disseminated diffusely
throughout the brain (Type 3 growth pattern) (Figures 3
and 4). Individual optical sections from corresponding
areas of T98G control and TWIST1 tumors (Figure 3)
and a brightest point projection image (BPI) (Figure 4)
which sums the individual signals through the entire
Z-stack onto a 2-dimensional image, demonstrated the
differences in growth patterns. The growth pattern for
all tumors generated from T98G TW cells appeared to
coincide with white matter tracts and crossed midline
(Figure 3), both recognized primary routes of human
GBM tumor cell invasion. Taken together these results
provided critical confirmation of the pro-invasive func-
tion of TWIST1 in GBM cells in the context of the
brain microenvironment and demonstrated cell-type-
specific variability in TWIST1-mediated patterns of
invasion.
Figure 1 TWIST1 over-expression increases invasion of SNB19 and T98G cells in organotypic brain slice. (A) Representative low
magnification (4×) images of SNB19 Ctrl and TWIST1 (TW) expressing cells cultured on the brain slices (a). Magnified sub-regions indicated by
boxes in the top row are shown below (b). Cells invading brain tissue are shown with arrows. Scale bars: 500 and 200 μm. (c) Quantified cell
migration is shown on the bar diagram (p = 0.0002). Brain slices were imaged using laser scanning confocal microscopy at equivalent optical
planes and analyzed using Metamorph software. (B) (a): Low-magnification photomicrograph of merged fluorescent and DIC channel images.
(Left) T98G control (Ctrl) cells generate defined cell aggregates in the brain slice surface. (Right) T98G cells with TWIST1 (TW) over-expression are
dispersed as single cells and small non-cohesive aggregates over the brain slice. (b): Representative laser scanning confocal images of T98G Ctrl
and T98G TW slices. Images obtained through the entire thickness of the brain slice and 50 μm sections (as indicated by white lines) were
digitally reconstructed in the orthogonal plane for analysis of invasive cells. (c) Representative orthogonal views for T98G (Ctrl) and T98G TW are
presented as a maximum-intensity projection image. Arrows show cell aggregates on the surface of the slice and arrowheads show invading
cells. (d) The results of the analysis of invasive cell density demonstrated a significant increase in the invasion of T98G TW (7564 +/- 1771 cells/
mm
3) versus T98G control cells (1695 +/- 847 cells/mm
3), p = 0.007.
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profiles consistent with invasion
To characterize the molecular basis of TWIST1 expres-
sion and associated pro-invasive phenotypes we com-
pared expression profiles of SNB19 and T98G cells with
TWIST1 over-expression and corresponding control
cells using Affymetrix gene expression arrays. Overall,
TWIST1 over-expression led to differential regulation of
1924 genes in SNB19 and 1525 genes in T98G cell lines
(1.5 fold, p < 0.05). Among these, 189 common genes
were differentially regulated by TWIST1 over-expression
in both cell lines (Pearson’s correlation 0.557; p < 0.05;
Additional file 3). Using GO analysis we determined
biological process gene categories that were significantly
altered by TWIST1 over-expression (FDR = 0.1). In
both cell lines TWIST1 over-expression resulted in con-
sistent and significant over-representation of genes in
GO biological process categories including cell adhesion,
extracellular matrix, cell motility and locomotion, cell
migration and actin cytoskeleton organization (Figure 5).
Of note, these categories are fundamental biological pro-
cesses that are component features collectively required
to achieve cell invasion [1,13]. GO biological process
categories unique to SNB19 included enzyme-linked
receptors and transcription while T98G cell type-specific
categories included development, morphogenesis and
intracellular signaling cascade. Of interest, a significant
over-representation of genes in nervous system
Figure 2 TWIST1 over-expression increased invasiveness of SNB19 cells in vivo. (A) Representative images generated after intracranial
injection of GFP-labeled SNB19 Ctrl (left) and SNB19 TW cells (right) show isolated and aggregate cell invasion adjacent to a central tumor core
(type 2 growth pattern). Each 3-D confocal image is from a representative individual axial brain slice used for reconstruction of the growth
pattern of the total tumor. After imaging and reconstruction, whole brain images were analyzed using Huygens software. The number of
invasive aggregates (B), and total volume (VoxVol) of invasive aggregates per tumor (C) were significantly greater in SNB19 TW cells compared
with controls (p = 0.0037 and 0.0166, respectively). Arrows demonstrate invasive cell aggregates around central tumor core.
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Page 4 of 18development, a daughter category with the parent cate-
gory of development, was also noted in T98G TW cells.
T h es p e c i f i cg e n e sr e g u l a t e db yT W I S T 1i nt h e s ec e l l
lines are discussed in more detail below. While this ana-
lysis demonstrated that cell type-specific changes in
functional gene expression occur in GBM cells over-
expressing TWIST1, we found that TWIST1 most con-
sistently activated common molecular motifs related to
cell invasion in both GBM cell lines.
TWIST1 mediated alteration of cell-cell adhesion, cell-
substrate interactions, migration, and actin cytoskeleton
in glioma cells
To determine whether the GO analysis was consistent
with TWIST1-mediated cellular phenotypes we per-
formed functional assays in SNB19 TW cells for changes
in cell-cell adhesion, cell-substrate interactions, migra-
tion and actin cytoskeleton compared to control cells
(SNB19 Ctrl) (Figure 6). SNB19 TW cells formed far
f e w e ra n ds m a l l e rc e l l u l a ra ggregates compared with
control cells indicating a significant change in cell-cell
interactions (Figure 6A). Cell substrate interaction,
tested by cell plating on fibronectin (FN) showed over
100% greater adhesion of SNB19 TW cells than control
cells compared with no significant change found when
cells are plated on bovine serum albumin (Figure 6B).
Migration of SNB19 TW cells through an uncoated fil-
ter membrane increased 40% compared with controls
(Figure 6C). Consistent with increased migration, SNB19
TW cells showed reorganization of actin cytoskeleton
with increased lamellipodia formation associated with
activation of focal adhesion kinase (FAK) at leading
edges (Figure 6D). Together, these results demonstrated
a concordant relationship between the TWIST1-
mediated program of gene expression and cellular phe-
notypes. Furthermore these data indicated that TWIST1
regulates the multiple individual cellular changes (altera-
tion of cell-cell interaction, cell-substrate interactions
and reorganization of actin cytoskeleton to facilitate
migration) that together comprise the carefully orche-
strated process of glioma invasion.
TWIST1 activates expression of mesenchymal genes
without cadherin switch
The previous data demonstrated that TWIST1 over-
expression promoted an invasive mesenchymal cellular
Figure 3 TWIST1 over-expression increased invasiveness of T98G cells in vivo. Equal numbers of GFP-labeled T98G Ctrl and T98G TW cells
were injected into SCID mouse brains. At three months, whole brains were isolated and imaged using laser scanning confocal microscopy. For
each tumor three optical sections for corresponding levels within each tumor are shown (left -top of the tumor; center - middle of the tumor;
right - bottom of the tumor). Dashed white vertical and horizontal lines correspond to anterior border of brain and midline, respectively. The
solid red line corresponds to the fixed coronal plane through the site of injection. Whole brain picture (lower left panel) demonstrates site of
injection and approximate borders of the confocal images. In contrast to the fixed position of tumor growth at the injection site for the T98G
Ctrl tumor, the T98G TW tumor demonstrates a marked degree of tumor cell migration anterior and posterior to the plane of injection and
across the midline.
Mikheeva et al. Molecular Cancer 2010, 9:194
http://www.molecular-cancer.com/content/9/1/194
Page 5 of 18phenotype in GBM cells. Given that TWIST1 promotes
carcinoma invasion and metastasis through activation of
EMT we sought to determine whether TWIST1 acti-
vated molecular features associated with carcinoma
EMT in GBM cells. Within GO categories common to
both SNB19 and T98G, approximately 1/3 of genes
were upregulated in both cell lines while 2/3 were cell-
type specific (Additional file 4, Table S1, S2). Many of
these were genes known to promote mesenchymal
changes in epithelial cancers (Table 1). Differential
expression of a subset of genes selected from the arrays
was validated by comparing expression in microarray
with qRT-PCR (Figure 7). Genes associated with EMT
were regulated by TWIST1 in SNB19 and/or T98G
GBM cells including extracellular matrix proteins fibro-
nectin 1 (FN1) [14], periostin (POSTN) [15] and SPARC
[16-18] protease MMP2 [19,20], transcription factor
SNAI2 [21-23] transcriptional modifier ID1 [24], growth
factor HGF [21,25] lysyl oxidase (LOX) [26] and cell
adhesion protein cadherin 11 (CDH11) [27]. Other
genes associated with mesenchymal phenotypes and
glioma invasion, not yet formally linked to EMT,
included laminin, alpha 4 (LAMA4) [28] and fibroblast
activation protein alpha (FAP) [29].
Perhaps the most widely used marker for EMT in
carcinomas is loss of E-cadherin and upregulation of N-
cadherin, or the “cadherin switch”. To determine whether
TWIST1 activated a “cadherin switch” in GBM cells, we
quantified E-cadherin and N-cadherin mRNA expression
in a panel of GBM cell lines each with vector control or
TWIST1 over-expression. We found no consistent rela-
tionship between endogenous levels of E- or N-cadherin
Figure 4 Brightest point projection images (BPI) of tumor growth patterns. The same tumors shown in Figure 3 were analyzed using BPI
to visualize global differences in tumor growth patterns. Control T98G and T98G TWIST1 over-expressing tumor images are generated from total
of 140 and 164 optical sections, respectively, collected by confocal microscope using ImageJ software. Control tumors possess a more cohesive
pattern and localized growth pattern while T98G TW tumors demonstrate a markedly diffuse pattern of growth (type 3 invasive growth pattern).
Arrows indicate regions of diffuse T98G TW tumor cell outgrowth.
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importance, in no case did TWIST1 over-expression
result in combined reductiono fE - c a d h e r i na n du p r e g u -
lation of N-cadherin. These data indicated that the cano-
nical “cadherin switch” central to TWIST1-mediated
EMT in carcinomas does not occur in GBM cell lines
over-expressing TWIST1 nor is it required to promote
an invasive mesenchymal phenotype in human GBM
cells. In only one of four cell lines (SNB19) in which
TWIST1-mediated invasion was formally tested, did E-
cadherin expression decrease with TWIST1 over-expres-
sion (Figure 8C). While TWIST1 over-expression
resulted in decreased cell-cell adhesion in SNB19 in asso-
ciation with reduced E-cadherin expression, a similar
decrease in cell-cell adhesion was noted for T98G TW
cells versus vector controls (data not shown) despite the
absence of detectable E-cadherin in control cells.
Together these findings indicated that mechanisms inde-
pendent of the E- to N-cadherin switch promote
TWIST1-mediated GBM cell invasiveness. However, the
commonality of genes regulated by TWIST1 in GBM cell
lines and carcinoma metastasis suggested that the mole-
cular program in GBM does partially overlap with that of
TWIST1-mediated EMT in carcinomas.
TWIST1 expression highly correlates with in vitro TWIST1
target genes in human glioma samples
To determine whether expression of putative TWIST1 tar-
gets identified in microarrays are clinically relevant we
compared expression of SNAI2 (upregulated 6.6 fold in
SNB19 TW cells) and FAP (upregulated 36 fold in SNB19
and 6.5 fold inT98G). These genes were selected for study
because of their characterized roles in carcinoma EMT
invasion and metastasis [30] and their reported upregula-
tion in malignant gliomas [31,32]. In a set of 39 human
glial neoplasms using quantitative RT-PCR we found a
significant correlation between TWIST1 and SNAI2
(r = 0.72; p = 0.001) and TWIST1 and FAP alpha (r = 0.57,
p = 0.001) message levels (Figure 9A, B). Compared to nor-
mal brain controls, the mean TWIST1, SNAI2 and FAP
expression were all up-regulated in the most malignant
grade IV gliomas compared with grade II and III tumors (p
= 0.022, p = 0.0014, p = 0.005, respectively) (Figure 9C, D,
E). Consistent with their roles in mesodermal development
and mesenchymal differentiation, the highest expression
levels for all genes were evident in grade IV gliosarcoma
tumors, which have the highest degree of overt mesenchy-
mal differentiation among all gliomas. These results
demonstrated for the first time a close association between
expression of TWIST1 and putative TWIST1 target genes
also implicated in both carcinoma and glioma malignancy.
T oc o n f i r mt h a tp u t a t i v eT W I S T 1t a r g e t sp l a yar o l ei n
glioma cell invasiveness, we overexpressed SNAI2 in
SNB19 cells and found that SNAI2 was sufficient to
increase SNB19 cell invasion 80% (Additional file 5).
Together our results support the relevance of our in vitro
model of TWIST1 function to identify candidate mechan-
isms of TWIST1-mediated invasion.
Figure 5 TWIST1 over-expression results in over-representation of common GO categories related to mesenchymal phenotype and
invasion. To characterize changes in gene expression due to TWIST1 over-expression, we compared global gene expression in vector control
and TWIST1 over-expressing SNB19 and T98G cells using the Affymetrix GeneChip platform. The analysis revealed many common categories
identified by GoMiner (FDR cut-off level <0.1) that are related to mesenchymal function and invasion (cell adhesion, extracellular matrix, cell
migration, cell motility and locomotion, and actin cytoskeleton organization) as well as cell-line specific categories consistent with TWIST1
function (transcription and organ development and morphogenesis, e.g.). The number of up- and down-regulated genes in each category is
shown. The individual genes that comprise each category are provided in Additional file 4, Table S1.
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expression
Our results demonstrated that increased levels of
TWIST1 expression correlate with increased cell
invasiveness. To determine whether inhibition of
TWIST1 expression may have therapeutic relevance we
investigated the effects of TWIST1 knockdown on cell
invasion and glioma stem cell proliferation as well as
tumor sphere formation using sequence-specific shRNA
lentiviral constructs. In SNB19 and T98G cell lines,
decreasing levels of TWIST1 message and protein
resulted in inhibition of invasion. For SNB19, a 40%
Figure 6 TWIST1 over-expression produces mesenchymal cellular changes consistent with changes in gene expression. GO analysis of
gene expression predicted that TWIST1 would impact cellular phenotype and generate mesenchymal changes relevant to cell invasion. We
tested this prediction in SNB19 cells using multiple cell-based assays. (A) TWIST1 inhibits cell aggregation. Representative (4×) image of cell
aggregation of SNB19 Ctrl vs SNB19 TW cells (top row). Magnified (20×) sub-regions indicated by boxes in top row are shown below. (B) TWIST1
over-expression promoted adhesion to FN but not BSA-coated plates (shown as percent relative SNB19 control cells; mean ± SE). (C) Migration
of SNB19 Tw cells through a filter membrane is increased 40% compared with SNB19 Ctrl cells. (D) Cell morphology, actin cytoskeleton
architecture and FAK phosphorylation are altered by TWIST1. Representative (60×) photomicrographs of TWIST1 over-expressing and SNB19
control cells stained with anti-phospho-Tyr397 FAK (pFAK) antibodies (green), phalloidin-TRITC (red) and DAPI (blue). Phospho-FAK co-localization
with F-actin along the border of lamellipodia in SNB19 TW and control cells is shown with large arrows and small arrows, respectively. Scale bar
=1 8μm.
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Page 8 of 18suppression of TWIST1 mRNA (not shown) and con-
current reduction in protein levels reduced invasion 53%
(Figure 10A) while in T98G cells an 80% reduction of
TWIST1 mRNA levels (not shown) and concurrent
reduction in protein levels resulted in 40% inhibition of
invasion through matrigel (Figure 10B). Invasion was
compared to control cells stably infected with shGFP
lentiviral constructs. These controls did not affect
TWIST1 expression or invasion compared with the par-
ental cells not infected with shGFP lentivirus (data not
shown). A second, independent TWIST1-specific
shRNA construct resulted in similar reductions of
TWIST1 mRNA and invasion (data not shown). Finally,
to demonstrate the specificity of the TWIST1 shRNAs
we quantified their effects on the highly related gene
DERMO1/TWIST2 and found no changes in its expres-
sion (data not shown). Using well-characterized glioma
stem cells [12] we then tested the effect of TWIST1
inhibition on sphere-forming activity. Sphere number
measures the frequency of cells capable of proliferating
Table 1 EMT and invasion genes regulated by TWIST1 in SNB19 and/or T98G GBM cell lines
Gene
symbol
Gene ID Gene name Fold differences
SNB19 T98G
SNAI2 213139_at snail homolog 2 7.4 1
ID1 208937_s_at inhibitor of DNA binding 1 2.0 2.1
ID2 213931_at inhibitor of DNA binding 2 1.9 1.9
LOX 204298_s_at lysyl oxidase 12 1
TIMP3 201149_s_at TIMP metallopeptidase inhibitor 3 7.5 1
SPARC 212667_at secreted protein, acidic, cysteine-rich 2.0 1
PDGFRB 202273_at platelet-derived growth factor receptor 4.0 1
LAMA4 202202_s_at laminin, alpha 4 7.7 4.8
FN1 216442_x_at fibronectin 1 3.4 1
CDH11 236179_at cadherin 11, type 2, OB-cadherin (osteoblast) 5.9 2.3
MMP2 201069_at matrix metallopeptidase 2 12.7 1
FAP 209955_s_at fibroblast activation protein, alpha 33.3 6.5
HGF 209960_at hepatocyte growth factor 18 1
DSP 200606_at Desmoplakin -15.2 -3.8
IL8 211506_s_at interleukin 8 7.5 12.1
POSTN 2105809_s_at Periostin 1 22.8
Figure 7 Confirmation of the microarray results by qRT-PCR. To validate the results from microarray experiments we compared the
expression of selected genes related to EMT and/or carcinoma or GBM invasion identified in microarrays (see Tables 1 and Additional file 4,
Table S1) with qRT-PCR from mRNA extracted from independent samples of SNB19 (A) and T98G (B) cells with and without TWIST1 over-
expression.
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Page 9 of 18to form cell clusters while sphere size reflects the
growth potential of each sphere. With 80% inhibition of
TWIST1 expression in GBM6 stem cells, mean sphere
size was reduced 48% (p < 0.0001) (Figure 10 C-E). In
the GBM8 tumor stem cell line, similar 80% inhibition
of TWIST1 message (data not shown) resulted in a
marked decrease in the number of wells that formed
tumor spheres when plated at clonal dilution (30% vs.
67% in control GBM8 cells; p = 0.0033) and the mean
number of spheres in each well containing spheres (1.0
vs 2.3 for control GBM8 cells; p = 0.002) (see Table 2).
Together these results indicated the potential therapeu-
tic relevance of TWIST1 inhibition for invasion and
abrogation of glioma stem cell properties.
Discussion
The fundamental role for mesenchymal change in pro-
moting invasion, malignancy treatment response and
even cancer stem cell function in human carcinoma
and GBM invasion is increasingly recognized [8,9].
Figure 8 TWIST1 over-expression does not generate an E- to N-cadherin switch in GBM cell lines. Absolute quantification of E-cadherin
(A) and N-cadherin (B) mRNA expression levels in GBM cells by qRT-PCR demonstrates variable levels of gene expression. Of note, E-cadherin is
low or barely detectable in two of five lines tested. (C) Relative quantification of E- and N-cadherin gene expression in GBM cell lines with
TWIST1 over-expression relative to control cells transduced with empty vector (accepted as 1 and shown as horizontal line). E-cadherin
expression change is not shown for T98G because of expression levels close to background (see panel A). Contrary to carcinoma cells where
TWIST1 expression activates a “cadherin switch” TWIST1 over-expression in GBM cell lines did not reduce E-cadherin expression concurrent with
increased N-cadherin in any line tested.
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in carcinoma [5] but its relevance to invasion and
mesenchymal change in GBM models has not been
studied. Since tumor invasion is perhaps the major
obstacle to improved outcome for patients with carci-
nomas and gliomas the elucidation of TWIST1 func-
tion in GBMs is potentially of great clinical
importance. Following on our previous observation in
t h eS F 7 6 7G B Mc e l ll i n e[ 1 1 ]t h i ss t u d yv a l i d a t e dt h e
pro-invasive function of TWIST1 in multiple cell lines
in vitro and in vivo a n dd e m o n s t r a t e dt h a tT W I S T 1
promoted clinically relevant mesenchymal molecular
and cellular phenotypes that partially recapitulated
those associated with carcinoma EMT. These findings
identify TWIST1 as a regulator of mesenchymal
change and invasion in GBM that can be leveraged for
further investigation of the clinical potential of sub-
verting mesenchymal change as a therapeutic strategy
in treating GBM.
Collectively TWIST1 promoted invasion in vitro of all
GBM cells tested to date (including a GBM stem cell
line). We further established that TWIST1 enhanced
invasion in the more relevant settings of brain slice cul-
ture and orthotopic xenotransplant models using SNB19
and T98G GBM cell lines. Of interest, the patterns of
enhanced invasion generated by TWIST1 over-expres-
sion were cell-line specific with SNB19 TW cells invad-
ing as single cells or small aggregates from a central
core while T98G TW cells diffusely invaded throughout
the brain. These extreme patterns of invasion are similar
to those in cases of gliomatosis cerebri [33]. These find-
ings clearly demonstrate the generic pro-invasive func-
tion for TWIST1 in GBM and suggest that cell-intrinsic
factors can modify TWIST1- mediated patterns of GBM
invasion.
Consistent with this, TWIST1 over-expression gener-
ated cell-specific changes in gene expression with shared
pro-invasive functional attributes. TWIST1-mediated
Figure 9 Clinical relevance of putative TWIST1 in vitro target genes: SNAI2 and FAP were identified as putative TWIST1 target genes
in SNB19 and/or T98G cells. The expression of SNAI2 (A) and FAP (B) are highly correlated with TWIST1 expression in a group of 39 glial
tumors of different grade and type including 9 grade II, 3 grade III and 27 grade IV (21 GBM, 6 gliosarcoma (GS) [open circles]) gliomas. ΔCt (dCt)
values were determined by qRT-PCR. Correlation coefficients and p values are shown in insets. (C, D, E) The expression levels of TWIST1, SNAI2
and FAP relative to normal brain in different grades of glioma (II+III vs IV) and in the grade IV sub-types (GBM and gliosarcoma (GS)) are shown.
Expression of TWIST1, SNAI2 and FAP are higher in grade IV gliomas (GBM and GS) compared to grades II and III combined (p = 0.022, p =
0.0014, p = 0.005, respectively). Analysis of grade IV tumors demonstrated higher levels of TWIST1, SNAI2 and FAP expression in GS compared to
GBM (right side of each expression panel) (p = 0.0003, p = 0.0001, p = 0.0014, respectively). Horizontal bars show mean value of expression for
each group of tumors. (*, ** p < 0.05). Statistical analysis was performed using log transformed relative expression values.
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Page 11 of 18changes in expression of specific genes in SNB19 and
T98G were heterogeneous but overlapped at the func-
tional level within five common categories related to the
cellular requirements for glioma invasion and EMT
including cell adhesion, extracellular matrix, cell motility
and locomotion, cell migration and actin cytoskeleton
organization. Importantly, TWIST1 over-expression
Figure 10 Inhibition of TWIST1 expression decreases glioma cell invasion and stem cell activity. (A) Top panel: Endogenous levels of
TWIST1 protein expression in nuclear extracts from SNB19 cells transduced with shGFP (shCtrl) or shTWIST1 (shTW). Levels of Ini1 protein were
used as a loading control for Western blot analysis. Bottom panel: Quantification of SNB19 shTW invasion relative to control cells (shCtrl)
accepted as 100%. Representative images of membranes demonstrating reduced invasiveness of SNB19 shTW cells through matrigel relative to
control cells are shown. (B) Endogenous levels of TWIST1 protein expression in nuclear extracts from T98G cells transduced with shGFP (shCtrl)
or shTWIST1 (shTW). Levels of Ini1 protein were used as a loading control for Western blot analysis. Bottom panel: Quantification of T98G shTW
invasion relative to control cells (shCtrl) accepted as 100%. Representative images of membranes demonstrating reduced invasiveness of T98G
shTW cells through matrigel relative to control cells are shown. (C) Inhibition of TWIST1 mRNA expression by 80% was achieved in GBM6 glioma
stem cells transduced with shTWIST1 resulting in reduced sphere size. (D) Phase contrast image of representative GBM6 spheres transduced with
control or TWIST1 specific shRNA lentivirus shows dramatic qualitative reduction in sphere size (E) Quantification of mean sphere diameter in
GBM6 control or shTW cells confirms significant decrease in sphere size due to inhibition of TWIST1 expression (p < 0.0001).
Table 2 TWIST1 knockdown reduces sphere-forming
activity of GBM8 stem cells
Cell
type
Percent wells with
spheres
Number of spheres/well
+/-SE
shCTRL 67 2.3+/-0.3
shTW 30* 1+/-0.1**
* p = 0.0033; ** p = 0.002
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Page 12 of 18generated cell phenotypes highly consistent with the
over-representation of genes within these functional
categories that reflect critical individual cellular features
required for carcinoma and GBM invasion [1]. We also
determined that TWIST1 induced re-localization of acti-
vated FAK to sites of abundant lamellipodia formation, a
significant finding given the association between FAK
activation, cytoskeletal organization and its role in EMT
and glioma malignancy (reviewed in [34-36]. Loss of api-
cal-basal polarity (relative to a basement membrane) is
an additional feature of EMT in carcinomas which was
not tested here since assays of polarity for GBM cells in
vitro are not well established. However, the recent
description of polarized ciliated neural stem cells within
the ventricular zone neuroepithelium [37-39] suggests
that such studies could be attempted in situ or with
novel co-culture systems or at earlier stages of glioma
development. This approach could reveal polarity
changes (analogous to carcinoma EMT) as fundamental
steps in the process of gliomagenesis and acquisition of
an invasive phenotype. Together gene expression analy-
sis and cellular assays demonstrated that TWIST1 over-
expression in glioma cells orchestrated the acquisition
of a robust mesenchymal phenotype and cellular
changes that closely mirror those of carcinoma cells
undergoing mesenchymal transformation [40] and
required for tumor invasion and metastasis [41].
TWIST1-mediated molecular changes also provided
important insight into its role in mesenchymal change
in GBM. Many genes related to carcinoma EMT were
also up-regulated by TWIST1 in GBM indicating poten-
tial mechanistic overlap between the two processes.
However, the lack of a TWIST1-mediated “cadherin
switch” in GBM cells suggested that alternative mechan-
isms in nervous tissue and gliomas function to modulate
cell adhesion and invasion. Alternatively, a cadherin
switch could occur early in gliomagenesis or require
specific anatomic or environmental interactions not pre-
sent in our experimental system. The recent discovery
that normal neural stem cells – putative GBM cells of
origin – express E-cadherin supports this possibility
[42,43]. Further studies are warranted to examine the
impact of TWIST1 and other factors related to
mesenchymal change in normal GBM cells of origin
(neural stem and progenitor cells) or in cells at early
stages of gliomagenesis to better define how alterations
in E-cadherin or other cell-cell adhesion molecules
impact the acquisition of an invasive malignant
phenotype.
The clinical relevance of identified putative TWIST1
targets was established through correlation between
TWIST1, SNAI2 and FAP expression levels in 39
human gliomas of different grades. These studies
demonstrated that the current in vitro model of
TWIST1 pro-invasive function was capable of identify-
ing clinically relevant pro-invasive targets and candidate
downstream mechanisms of TWIST1-mediated glioma
invasion. Our data also confirms prior reports that
expression of SNAI2 [31] and FAP [44] is directly linked
to malignant glioma grade and further showed that they
are coordinately upregulated in gliosarcoma, the grade
IV glioma with the most overt mesenchymal differentia-
tion. As regulators of invasiveness, TWIST1 and SNAI2
are potential targets for therapeutic modulation, a pro-
position further supported by their known functions to
promote cell survival and treatment resistance in other
cancer types [45-50]. FAP is expressed in wounds and
f i b r o t i ct i s s u e sa sw e l la sc a r c i n o m a - a s s o c i a t e df i b r o -
blasts in multiple cancer types and is thought to degrade
tumor matrix and facilitate carcinoma invasion [51].
Further studies are needed to determine which cell type
( s )e x p r e s sF A Pa n dw h e t h e ri ts e r v e sas i m i l a rr o l eo f
altering tumor stroma to promote invasion in GBM.
T h es i g n i f i c a n c eo fT W I S T 1f u n c t i o nt op r o m o t e
invasion through mesenchymal change in GBMs is
underscored by recent reports of clinically relevant
mesenchymal phenotypes in GBMs. Gene expression
array studies identified a mesenchymal stem cell (MSC)
phenotype in human GBMs [10] and distinct pro-neural,
proliferative and mesenchymal gene expression signa-
tures among malignant grade III and IV human gliomas
[9]. The mesenchymal signature is associated with poor
prognosis, increased angiogenesis and tumor recurrence
[9]. Therefore, along with other transcription factors
such as STAT3 and C/EBP which were recently identi-
fied as regulators of mesenchymal transformation in
GBM cells [8] the correlation of TWIST1 with induction
of mesenchymal changes, increased glioma grade and
invasiveness implicate TWIST1 as an additional central
regulator of this process in human GBM. Of note,
STAT3 transcriptionally upregulates TWIST1 expres-
sion and promotes breast carcinoma cell migration [52]
prompting speculation that STAT3-TWIST1 interac-
tions in GBM may also contribute to invasion and
mesenchymal change.
Inhibitors of TWIST1 are not available; therefore, to
investigate the therapeutic relevance of inhibiting
TWIST1 in GBM we knocked down TWIST1 expres-
sion using shRNA and assayed its effects on cell inva-
sion and glioma stem cell properties. Specific inhibition
of TWIST expression resulted in marked reductions in
glioma cell invasion in vitro. These findings are consis-
tent with the pro-invasive function of TWIST1 in GBM
and support the therapeutic potential of inhibiting
TWIST1 or TWIST1-mediated signaling to inhibit
GBM invasion. Glioma stem cells are recognized as
tumor-initiating cells that determine tumor malignancy
and growth. Through activation of EMT, TWIST1
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Page 13 of 18promotes the formation and maintenance of breast can-
cer stem cells [53] and TWIST1 over-expression is
implicated in mesenchymal stem cell activity [54]. Given
these observations we propose that targeting TWIST1
may have additional therapeutic relevance in gliomas by
abrogating glioma stem cell functions. Our data showed
that inhibition of TWIST1 expression resulted in a dra-
matic reduction in GBM stem cell sphere formation and
growth. These results suggest that a unique therapeutic
potential of inhibiting TWIST1 may result from simulta-
neous targeting of glioma cell invasiveness and stem cell
function – hallmark GBM properties that both contri-
bute to tumor growth, progression and treatment resis-
tance. To address this potential, ongoing and future
studies will address the effects of TWIST1 inhibition in
GBM cells on tumor growth, invasion and response to
therapy in vivo.
Conclusions
Together these studies demonstrated that TWIST1
enhances GBM invasion in concert with mesenchymal
changes. However, these changes do not involve the cano-
nical cadherin switch of carcinoma EMT. The present
findings demonstrated the potential usefulness of applying
carcinoma EMT as a framework from which to enhance
our understanding of GBM invasion and further suggest
that a neural form of mesenchymal change, analogous to
carcinoma EMT, may contribute broadly to glioma malig-
nancy. Based on these findings we propose targeting
TWIST1-mediated mesenchymal change as a therapeutic
strategy with potential to inhibit GBM invasion and tumor
growth, and enhance treatment responses.
Methods
Cell lines and tissue
Glioblastoma cell lines T98G, SNB19, SF767, U87MG
were maintained in DMEM/F12 with 10% FBS
(Hyclone). Human primary GBM cancer-initiated cells
(GBM4, GBM6) were cultured as described [12] in the
presence of EGF and bFGF. Human glioma tumor sam-
ples were acquired according to a protocol approved by
the Institutional Review Board of the Human Subjects
Division of the University of Washington. Samples were
immediately snap frozen in liquid nitrogen and stored at
-80°C before processing. Type and grade of tumors were
confirmed by histopathological examination.
Expression and shRNA constructs, and cell transduction
A retroviral human TWIST over-expression construct
and methods for infection of SNB19 and T98G cell lines
were described previously [11]. Myc-tagged SNAI2
expression construct (SNAI2myc) was generated by PCR
followed by subcloning in LXSN expression vector. Exo-
genous protein expression was confirmed by Western
blot analyses with corresponding antibody. Lentiviral
shRNA construct for inhibition of TWIST1 expression
[ 5 ]a n dc o n t r o ls h R N Aw e r ep u r c h a s e df r o mA d d g e n e .
Lentivirus was generated using a standard method in
HEK293T cells. A pool of infected cells was selected
with Puromycin (1 μg/mL).
Cell aggregation assay
Single-cell suspensions (10
5 cells/mL in DMEM-F12
without FBS) were plated into each well of a 6-well
plate coated with 0.6% agarose/DMEM-F12. The plate
was incubated at 37°C on a rocking platform for 16 hrs.
Cells were fixed in 5% formalin to preserve cell-cell
interactions and photographed.
Cell adhesion
SNB19 LXSN and TWIST cells (5 × 10
4/1 mL) were
allowed to adhere to 24-well plates coated with BSA or
fibronectin (5 μg/mL) for 1 hour. Cells were then
washed, fixed, stained and counted. Differences in cell
adhesion are shown as percent of SNB19 control cells
attached to BSA-coated wells. Three wells from 3 sepa-
rate experiments were analyzed and the significance of
differences was determined by Student t-test. Data
shown are mean ± SE.
GBM stem cell sphere assays
GBM6 and GBM8 stem cells with TWIST1 knockdown
and control cells (scrambled shRNA lentiviral vector)
were dissociated and viable cells were counted using
ViCell. Viable GBM6 cells plated at 3200 cells per well
in 6-well plates were used to establish the effect of
TWIST1 knockdown on sphere size. After 5 days
spheres were photographed and sphere sizes were mea-
sured using Adobe Photoshop. To determine the effects
of TWIST1 on sphere-forming activity GBM8 cells were
plated at clonal dilution (20 viable cells per well in 96-
well plate). After 7 days, wells with spheres were
counted and presented as a percent of wells with
spheres. Average numbers of spheres per well with
spheres were also calculated. Fisher exact test and t-test
were used for statistical analysis as appropriate.
Immunocytochemistry and F-actin staining
Cells were grown in 8-well chambers and fixed in 4%
PFA for 10 min. Following treatment with 0.1% Triton
X-100/TBS for 5 min, cells were blocked in 1%BSA/
TBS, washed and incubated with FAK or phospho-FAK
antibody (Upstate) according to manufacturer protocol.
Appropriate secondary antibody conjugated with FITC
(Pierce) was used for antigen detection. F-actin was
stained with TRITC conjugated phalloidin (1 μg/mL)
followed by DAPI (1 μg/mL) staining. Antigens were
visualized using confocal microscopy (Delta-Vision).
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Cell harvesting, cell lysis and Western blot procedures
were performed as described previously [11]. Total cell
lysates were used for detection of TWIST1 over-expres-
sion. Nuclear extracts were used to increase assay sensi-
tivity in detecting endogenous TWIST1 expression. For
protein loading control, anti-b-actin antibody (Sigma)
for total proteins or Ini1 (H-300) antibody (Santa Cruz)
for nuclear proteins were used. Immunoblot for MycTag
Antibody (Upstate) was performed according to manu-
facturer’s recommendation.
Invasion and migration assays
The invasion and migration assays were performed
using 24-well Matrigel invasion chambers or uncoated
Control inserts (BD Biosciences) as previously described
[11]. Briefly, cells were resuspended in a serum-free
DMEM and loaded into inserts (5 × 10
4 cells/500 μL).
DMEM/F-12 with 10% FBS (SNB19) and without FBS
(T98G) was added to the lower chamber (750 μL). Fol-
lowing incubation at 37°C, cells that invaded or
migrated to the underside of the membrane were fixed,
stained, digitally imaged and counted. Differences in cell
invasion were expressed as a percent of invading/migrat-
ing relative to control cells. Data shown are mean ± SE.
Invasion in organotypic brain slices
Coronal brain slices (400 μm) from 21-day-old mice
were cultured as previously described in the media sup-
plemented with 10%FBS [55]. SNB19 or T98G cells with
LXSN or TWIST1 over-expression (labeled with GFP
expressing lentivirus) were placed at the corpus callo-
sum. After 10 days in vitro, the co-cultures were fixed
and analyzed by confocal microscopy. Slices were
imaged using a FluoView FV1000 confocal microscope
(Olympus). Collected Z-stacks were processed for visua-
lization and cell counting using NIH Image software.
The morphometric software Metamorph (Molecular
Devices Corporation) was used to measure cell migra-
tion. The distances from the border of the cells’ aggre-
gate to each of the 20 furthest cells were measured for
each of the 9 tissue slices (total n = 178 measurements)
and compared using a repeated measures ANOVA
model. The modeling was done with the ‘proc mixed’
procedure available in SAS.
Intracranial injection and whole brain imaging
Animal experiments were performed according to proce-
dures approved by the University of Washington IACUC.
Glioma cells harboring empty vector and cells with
TWIST1 over-expression were labeled with GFP-expres-
sing lentivirus (pLL3.7) prior to implantation. T98G cells
were injected in 9- to 10-week-old SCID-NOD mice.
SNB19 cells were injected in 7- to 8-week-old nude mice.
Following animal sedation 3 × 10
5 labeled cells were
injected intracranially into the right caudate nucleus
using a stereotactic apparatus and a Hamilton syringe.
To determine the effect of TWIST1 on tumor growth
and invasion, animals (6 mice with SNB19 TW and 4
mice with SNB19 Ctrl) were sacrificed 17 days after injec-
tion when the animals first showed signs of morbidity.
Animals injected with T98G TW or control cells (3 mice
per group) were sacrificed 90 days after injection. Ani-
mals were perfused with 4% paraformaldehyde (PFA).
The entire brain was dissected from the calvarial vault
and fixed for an additional 24 hours in 4% PFA at room
temperature with light agitation. Brains were washed
with PBS and transferred to 50% glycerol in PBS for 24
hours, 75% glycerol for 24 hours, then 90% glycerol at
4°C until imaged. The whole brain was sliced in the
axial plane to obtain 3 slices, each approximately 2 mm
thick. Each slice then was imaged using the FV1000
laser scanning confocal microscope in the axial plane to
detect GFP-expressing cells and perform automated
image splicing to reconstruct the entire tumor in a
single axial slice.
Image analysis for invasion
A semi-quantitative scale was used for initial characteri-
zation of tumor growth patterns as follows: Type 1 =
solid compact core with mainly localized expansile
growth; Type 2 = easily detectable non-contiguous indi-
vidual cells or cell clusters invading into brain parench-
yma adjacent to the solid tumor core; Type 3 = poorly
defined or absent core with diffusely invasive contiguous
or non-contiguous growth. Type 3 represents the most
invasive growth pattern. For circumstances where the
scale did not provide clear indications for the degree of
invasiveness, differences in tumor growth pattern were
quantified as follows: Reconstructed wide-field brain
images with tumors were analyzed using Huygens soft-
ware (Scientific Volume Imaging, Hilversum, The Neth-
erlands). Individual signal intensities from each
individual optical section (Z-stack images) collected by
confocal microscopy were integrated into a brightest
point projection image (BPI) to provide a 2-dimensional
summary of total tumor cell density and spatial distribu-
tions (Image J). Information collected includes tumor
core volume, invasive cell volume and a number of inva-
sive aggregates. Numerical values were compared using
t-test.
Microarray processing methods for the Affymetrix
microarray platform
Gene expression experiments were performed using the
GeneChip platform by Affymetrix (Santa Clara, CA) and
the manufacturer’s protocol. Statistical analysis and data
normalization for the Affymetrix arrays were carried out
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(Iobion Informatics LLC, La Jolla, CA). Modified t-test
was applied for two-group comparison. Bioconductor
was used to calculate p-values using a modified t-test in
conjunction with an empirical Bayes method to moder-
ate the standard errors of the estimated log-fold
changes. P-values were adjusted for multiplicity with the
program q-value. Genes with absolute change greater
than or equal to 1.5 fold and p < 0.05 were considered
differentially regulated by TWIST1. To demonstrate the
correlation of changes in expression (up or down-regu-
lation) between genes differentially regulated in both
cell lines, we applied a Pearson’s correlation analysis
using Bioconductor software (see above). Gene Ontology
(GO) categories were analyzed using GoMiner [57] to
detect gene category over-representation with cut off
false discovery rate (FDR) 0.1.
Quantitative RT-PCR (qRT-PCR)
Total RNA from cells, brain or tumor samples was
extracted using Qiagen RNeasy mini kit. RNA (1 μg)
was reverse-transcribed with Clontech kit. SYBR Green
PCR Master mix (ABI) was used for template amplifica-
tion. Thermocycling for all targets was carried out in 30
μL reaction for 40 cycles in triplicate. Each cycle con-
sisted of: 94°C for 15 seconds, 58°C for 30 seconds and
72°C for 30 seconds. For all samples, reactions were run
in triplicate. PCR reactions where reverse transcriptase
was omitted were used as negative controls. SYBR
Green incorporation was monitored in real time with an
ABI PRISM 7000 sequence detection system (Applied
Biosystems) and threshold exponential amplification
cycle (CT) was calculated by SDS system software. Dif-
ferences in the CT values (ΔCT) between the target tran-
script and GAPDH endogenous control determined the
relative gene expression level and the ΔΔCT method
was used to calculate fold differences in expression.
Relative expression in each tumor sample is normalized
by expression of corresponding target in a pool of nor-
mal brain samples (n = 4). Correlations between
TWIST1 and SNAI2 or FAP expression were calculated
using a regression coefficient and ΔCt values for each
tumor sample. Statistical analysis of relative expression
levels in human tumors was performed using unpaired
t-test. Relative expression values were log transformed
before testing to ensure normal distribution. Absolute
quantification was used to compare levels of E- and N-
cadherin mRNA expression. Standard curve was built
using plasmid harboring corresponding cDNA targets
diluted from 0 to 10
7 copies per reaction. Final results
are shown as a number of copies per μgo ft o t a lR N A .
The specificity of amplifications was confirmed by
amplicon melting profile.
Additional material
Additional file 1: Alteration of TWIST1 expression correlates with
cell invasiveness in vitro in SNB19 and T98G cells.(A) Top panel:
Detection of TWIST1 protein from whole cell lysates of a pool of SNB19
cells transduced with retroviral expression construct (TW) compared to
SNB19 cells transduced with empty vector (Ctrl). b-Actin is shown as
loading control. Bottom panel: Quantification of SNB19 Tw cell invasion
relative to Ctrl cells accepted as 100%. Representative images of
membranes demonstrating increased invasiveness of Snb19 Tw cells
relative to control cells are shown. (B) Top panel: Detection of
exogenous TWIST1 over-expression in cell lysates from T98G cells by
Western blot. Bottom panel: Quantification of T98G Tw cell invasion
relative to Ctrl cells accepted as 100%. Representative images of
membranes demonstrating increased invasiveness of T98G Tw cells
relative to control cells are shown.
Additional file 2: Over-expression of TWIST1 expression in GBM
stem cells correlates with cell invasiveness (A) Quantification of
exogenous TWIST1 over-expression using qRT-PCR in GBM4 primary GBM
stem cells cultured as neurospheres and transduced with TWIST1
retroviral expression vector. (B) Quantification of GBM4 cell invasiveness
in matrigel assay. Representative images of membranes demonstrating
increased invasiveness of GBM4 Tw cells relative to control are shown.
Differences in cell invasion are shown as percent of control cells
transduced with empty vector (mean ± SE).
Additional file 3: Pearson’s correlation of genes differentially
regulated by TWIST1 in T98G and SNB19 cells with TWIST1 over-
expression relative to corresponding controls. A total of 189 genes
(1.5 fold, p < 0.05) were differentially co-regulated by TWIST1 in both
T98G and SNB19 cells relative to corresponding controls.
Additional file 4: Supplementary Tables. Table S1. The list of
common and cell-specific differentially expressed genes within each GO
category over-represented in both SNB19 and T98G cells. Table S2.T h e
total number of genes within common categories shown in Table S1.
Additional file 5: Putative TWIST1 target SNAI2 is sufficient to
induce glioma invasiveness in vitro. (A) Exogenous over-expression of
Myc-tagged SNAI2 in SNB19 cells. (B) Quantification of invasion of SNB19
cells with SNAI2 over-expression. Representative images of invasive cells
on the membrane are shown.
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